Purpose: The frequency of occult hepatitis B is variable in patients with cryptogenic cirrhosis and is unknown in our region. The presence of HBV DNA in serum of cirrhotic patients can be determined by molecular techniques despite the lack HBV serological markers. We aimed to determine the frequency of occult hepatitis B virus in patients with cryptogenic cirrhosis in this study. Materials and Methods: This cross-sectional study was designed to assess the prevalence of occult HBV infection in a group of patients with cryptogenic liver cirrhosis. Forty-four patients with cryptogenic cirrhosis who were examined in our hospital were enrolled in this study. Their serum were studied for HBV DNA levels using a real-time PCR method. Results: There were 44 patients in the study group;
Positive for anti-hepatitis B surface antibody was detected in 22 patients, and positive for hepatitis B core antibody was detected in 24 patients. In 2 patients, HBV DNA was found to be positive. In our study, occult HBV infection was found in 4.5% (2/44) 
INTRODUCTION
Hepatitis B virus (HBV) infection is one of the most common causes of acute and chronic liver disease (CLD) all over the world; it remains a serious global health problem¹. The course of chronic HBV infection progresses from light to active liver disease²‫.³׳‬ It is estimated that approximately one third of the world's population (2 billion people) have been exposed to this virus. It is known that about 3-4 million people carry HBV in Turkey⁴.
With the development of highly sensitive molecular techniques, HBV DNA has been detected more frequently in hepatitis B surface antigen-negative (HBsAg (−)) persons. The first occurrences were observed in 1980 in patients with hepatocellular carcinoma (HCC) or chronic hepatitis; these patients were hepatitis C virus negative [HCV (−)] and had no other underlying causes. In subsequent years, occult HBV infection (OHBI) has been observed in patients without liver disease and in persons with completely normal liver function⁵⁻⁸.
OHBI is defined as the existence of HBV DNA in serum, lymphocytes or liver in individuals with negative serum HBsAg levels. The presence of hepatitis B core antigen (HBc Ag) or anti-HBs may be positive or negative in these individuals⁵⁻⁷. Today, PCR can be used as a diagnostic tool for the detection of HBV DNA in patient serum. HBV DNA levels exist at low titers in patients with OHBI. Today, the clinical and biological spectra of OHBI are not precisely known. HIV infection, nonalcoholic liver disease, and other liver diseases (e.g., in HIV-infected and hemodialysis patients) may be associated with OHBI⁸⁻¹². OHBI can also serve as an additional risk factor for HCC, alcoholic cirrhosis, nonalcoholic fatty liver disease, and progression of HIV infection¹³‫.⁴¹׳‬ The gold standard method for the detection of OHBI is to demonstrate the presence of HBV DNA in the liver or serum. In most cases, it is not possible to detect HBV DNA in the liver. For this reason, the OHBI diagnosis is mostly based on the analysis of serum samples. However, general acceptance, OHBI is defined as the existence of HBV DNA in the livers of ones who test negative for HBsAg, regardless of the existence of HBV DNA in the sera¹³‫.⁶¹׳⁵¹׳‬ The etiology is unknown in 10% of patients with liver cirrhosis, termed cryptogenic liver cirrhosis¹⁶. Cryptogenic cirrhosis, literally meaning cirrhosis of obscure or unknown origin, is a diagnosis of exclusion. OHBI may be an important etiological cause of cryptogenic cirrhosis.
OHBI frequency is not known in patients with cryptogenic cirrhosis in our region. We aimed to determine the frequency of OHBI in patients with cryptogenic cirrhosis who have been monitored in our hepatology clinic.
MATERIALS AND METHODS
This cross-sectional study was conducted at the gastroenterology and hepatology clinic of Adana Numune Training and Research Hospital. The records were retrospectively reviewed. The study was approved by the Ethics Committee of Cukurova University (No:32-2016).
Between January 2010 and January 2017, 57 patients with cryptogenic cirrhosis were diagnosed in our clinic. Forty-four patients who were still alive and whose records were complete were included in the study.
A diagnosis of cryptogenic cirrhosis is typically given when all other causes of cirrhosis have been ruled out. Although biopsy is the gold standard for the diagnosis of cirrhosis, the diagnosis is usually made by the clinical, laboratory and radiological findings of liver failure and by the presence of portal hypertension. Forty-four patients were diagnosed with cryptogenic cirrhosis, according to the following criteria: Absence of viral etiologic agents such as HBs Ag, anti HCV; absence of serologic determinants of mitochondrial, nuclear, and smooth muscle antigens; normal levels of seruloplazmin, iron and alpha 1-antitrypsin; the absence of alcohol or other hepatic toxin use.
Blood samples were collected. Serological markers of liver function such as aminotransferase (AST), alanine aminotransferase (ALT), serum albumin, and bilirubin were assessed using an Abbott Architect 16200 autoanalyzer (Abbott Inc., Princeton, NJ, USA). Serological markers of HBV infection, such as HBs Ag, anti-HBc Ab, anti HBs Ab levels were assessed using the chemiluminescent microparticle immunoassay (Abbott Inc., Princeton, NJ, USA). All assay protocols, cutoffs and result interpretations were performed according to the manufacturers' instructions.
HBV DNA detection
A fully automated Cobas AmpliPrep instrument for nucleic acid extraction was used according to manufacturer's recommendations. This tool is an automated real-time PCR assay that targets the precore and core regions of the viral genome. HBV DNA levels were studied from 650 μL serum by this instrument. The data generated were analyzed by Amplilink software. HBV DNA quantities are uttered in international units per milliliter (IU/mL). The linear range of the system is 20-1.7 × 10⁸ IU/mL.
Statistical analysis
Descriptive statistical data were presented using SPSS. Data are presented as mean ± standard deviation.
RESULTS
Forty-four patients were enrolled in this study. The clinical and biochemical characteristics of the patients are shown in the table 1. Among the patients with cryptogenic cirrhosis, 29 (65.1%) were males and 15 (34.9%) were females (male to female ratio = 1.93). The mean age at the time of the study was 62.93 ± 14.11 years. The overall study group had a mild increase in serum transaminase levels, with median serum ALT and AST levels of 45 IU/L (range: 10-40 IU/L) and 48 IU/L (range: 0-40 IU/L), respectively. Furthermore, the bilirubin values of these patients were high and the albumin levels were low. Bilirubin and albumin values were 1.9mg/dL and (range: 0,3-1,2 mg/dL) and 2.7 g/dL (range: 3.4-5.4 g/dL), respectively. Although detection of HBV DNA is the gold standard for detection of occult infection, the presence of antibodies against HBV core antigen (anti-HBc) in peripheral blood is also very sensitive in the diagnosis of OHBI. The risk of occult hepatitis associated with anti-HBc seropositivity has been demonstrated extensively, and the presence of antibody response to HBc can be considered a sentinel marker of occult HBV infection. In some studies, OHBI is more common in patients who are positive for anti-HBc than in patients who are negative for anti-HBcAg¹¹‫.⁹²׳⁶²׳‬ In our study group, anti-HBc total positivity was 54%. Two patients with detectable HBV DNA were also positive for anti-HBc.
No other studies have investigated the frequency of OHBI in patients with cryptogenic cirrhosis in our country. The prevalence of OHBI has been reported to be 0%-36.4% in different patient groups and blood donors from Turkey. According to these studies, OHBI was 0%-36.4% in HCV(+) hemodialysis patients, 7% in HCV(−) hemodialysis patients, and 3.4%-19% in HBsAg(−) patients with detectable HBV DNA³⁰⁻³³].
Although OHBI may be a potential prognostic factor for CLD, information regarding effects of OHBI in patients with CLD is limited. The most important reason is that there are various limitations of the studies conducted to date. First, the detection of HBV DNA needs a liver biopsy; however, this is not routinely performed in clinical settings. In addition, these studies were conducted in small cohorts and heterogeneous populations and used cross-sectional methods or variable detection sensitivities for the analysis of liver or serum HBV DNA levels.
In all cases examined, liver biopsy specimens were unavailable; thus, we analyzed serum samples using real-time PCR, which may underestimate the prevalence of OHBI. The number of positive cases was thus insufficient to determine any correlation between OHBI and liver cirrhosis.
Our study revealed the incidence of OHBI to be 4.5% in patients with cryptogenic cirrhosis. OHBI can be a causative factor of cirrhosis and progressive liver decomposition in these patients. We recommend that patients with cryptogenic cirrhosis be examined for OHBI. It is also recommended that patients with OHBI be closely monitored and treated with highly potent antiviral drugs.
